Efficacy of β-lactam/β-lactamase inhibitors to treat extended-spectrum beta-lactamase-producing Enterobacterales bacteremia secondary to urinary tract infection in kidney transplant recipients (INCREMENT-SOT Project)
| dc.creator | Nicolas j Muller | |
| dc.creator | Oriol Manuel | |
| dc.creator | Hande Arslan | |
| dc.creator | Imran Hasanoglu | |
| dc.creator | Maria López Oliva | |
| dc.creator | Sheila Chiese | |
| dc.creator | Nicola Duccio Salerno | |
| dc.creator | Olivier Lortholary | |
| dc.creator | Mical Paul | |
| dc.creator | Anne Scemla | |
| dc.creator | Elisa Grazia Calvi | |
| dc.creator | Laurent Dewispelaere | |
| dc.creator | Paulo Henrique Orlandi Mourão | |
| dc.creator | Athina Pyrpasopoulou | |
| dc.creator | Iordanis Romiopoulos | |
| dc.creator | Elias Iosifidis | |
| dc.creator | Edson Abdala | |
| dc.creator | Marta Bodro | |
| dc.creator | Tania Mara Varejão Strabelli | |
| dc.creator | Noa Cohen'sinai | |
| dc.creator | María Carmen Fariñas | |
| dc.creator | Warren Lowman | |
| dc.creator | Marco Falcone | |
| dc.creator | Esra Kazak | |
| dc.creator | Mario Tumbarello | |
| dc.creator | Erika Lease | |
| dc.creator | Nina Nestorova | |
| dc.creator | Ligia C.pierrotti | |
| dc.creator | Francisco López'medrano | |
| dc.creator | Rafael San'juan | |
| dc.creator | Miguel Montejo | |
| dc.creator | Maristela p. Freire | |
| dc.creator | Elisa Cordero | |
| dc.creator | Miruna d. David | |
| dc.creator | Esperanza Merino | |
| dc.creator | Seema Mehta Steinke | |
| dc.creator | Paolo a. Grossi | |
| dc.creator | Ángela Cano | |
| dc.creator | Elena Pérez'nadales | |
| dc.creator | Elena m. Seminari | |
| dc.creator | Maricela Valerio | |
| dc.creator | Filiz Gunseren | |
| dc.creator | Meenakshi Rana | |
| dc.creator | Alessandra Mularoni | |
| dc.creator | Pilar Martín'dávila | |
| dc.creator | Christian Delden | |
| dc.creator | Melike Hamiyet Demirkaya | |
| dc.creator | Zeliha Koçak Tufan | |
| dc.creator | Belén Loeches | |
| dc.creator | Mario Fernández'ruiz | |
| dc.creator | Ranganathan n. Iyer | |
| dc.creator | Fabio Soldani | |
| dc.creator | Britt'marie Eriksson | |
| dc.creator | Benoît Pilmis | |
| dc.creator | Marco Rizzi | |
| dc.creator | Julien Coussement | |
| dc.creator | Wanessa Trindade Clemente | |
| dc.creator | Emmanuel Roilides | |
| dc.creator | Álvaro Pascual | |
| dc.creator | Luis Martínez'martínez | |
| dc.creator | Belén Gutiérrez'gutiérrez | |
| dc.creator | Jesús Rodríguez'baño | |
| dc.creator | Julian Torre'cisneros | |
| dc.creator | José María Aguado | |
| dc.creator | Terence yi Shern Kee | |
| dc.creator | Núria Sabé | |
| dc.creator | Mariana Camoez | |
| dc.creator | María a Domínguez | |
| dc.creator | Fidi Koppel | |
| dc.creator | Jaime Lora'tamayo | |
| dc.creator | Leyre Lopez'soria | |
| dc.creator | Ban Hock Tan | |
| dc.creator | Elias David'neto | |
| dc.creator | Flávio Jota de Paula e Flávia Rossi | |
| dc.creator | Jose Antonio Lepe | |
| dc.creator | Gabriel Bernal Blanco | |
| dc.creator | Cecilia Martín'gandul | |
| dc.creator | Noelia Balibrea | |
| dc.creator | Antonio Franco | |
| dc.creator | Robin Avery | |
| dc.creator | Darin Ostrander | |
| dc.creator | Daniela Dalla Gasperina | |
| dc.creator | Jordi Carratalà | |
| dc.creator | Cristina Rovelli | |
| dc.creator | Alejandra m Natera | |
| dc.creator | Manuel Recio'rufián | |
| dc.creator | Julia Guzmán'puche | |
| dc.creator | Cristina Leoni | |
| dc.creator | Patricia Muñoz | |
| dc.creator | Carlos Sánchez'carrillo | |
| dc.creator | Sara Lardo | |
| dc.creator | Deena Rose Altman | |
| dc.creator | Jesús Fortún | |
| dc.creator | Isabel Oriol | |
| dc.creator | Rosa Escudero | |
| dc.creator | Francesca Gioia | |
| dc.date.accessioned | 2023-07-04T20:46:10Z | |
| dc.date.accessioned | 2025-09-08T23:07:43Z | |
| dc.date.available | 2023-07-04T20:46:10Z | |
| dc.date.issued | 2021 | |
| dc.format.mimetype | ||
| dc.identifier.doi | 10.1111/tid.13520 | |
| dc.identifier.issn | 13982273 | |
| dc.identifier.uri | https://hdl.handle.net/1843/55781 | |
| dc.language | eng | |
| dc.publisher | Universidade Federal de Minas Gerais | |
| dc.relation.ispartof | Transplant Infectious Disease | |
| dc.rights | Acesso Restrito | |
| dc.subject | Sepse | |
| dc.subject | Transplante de rim | |
| dc.subject | Resultado de tratamento | |
| dc.subject | Infecções Urinárias | |
| dc.subject.other | Bloodstream infection | |
| dc.subject.other | Carbapenem-sparing regimen, | |
| dc.subject.other | extended-spectrum β-lactamaseproducing Enterobacterales, | |
| dc.subject.other | Kidney transplatation | |
| dc.subject.other | Outcomes | |
| dc.subject.other | Urinary tract infecction | |
| dc.title | Efficacy of β-lactam/β-lactamase inhibitors to treat extended-spectrum beta-lactamase-producing Enterobacterales bacteremia secondary to urinary tract infection in kidney transplant recipients (INCREMENT-SOT Project) | |
| dc.type | Artigo de periódico | |
| local.citation.epage | 16 | |
| local.citation.spage | 1 | |
| local.citation.volume | 23 | |
| local.description.resumo | Background: Whether active therapy with β-lactam/β-lactamase inhibitors (BLBLI) is as affective as carbapenems for extended spectrum β-lactamase-producing Enterobacterales (ESBL-E) bloodstream infection (BSI) secondary to urinary tract infection (UTI )in kidney transplant recipients (KTRs) remains unclear.Methods: We retrospectively evaluated 306 KTR admitted to 30 centers from January 2014 to October 2016. Therapeutic failure (lack of cure or clinical improvement and/or death from any cause) at days 7 and 30 from ESBL-E BSI onset was the primary and secondary study outcomes, respectively.Results: Therapeutic failure at days 7 and 30 occurred in 8.2% (25/306) and 13.4% (41/306) of patients. Hospital-acquired BSI (adjusted OR [aOR]: 4.10; 95% confidence interval [CI]: 1.50-11.20) and Pitt score (aOR: 1.47; 95% CI: 1.21-1.77) were independently associated with therapeutic failure at day 7. Age-adjusted Charlson Index (aOR: 1.25; 95% CI: 1.05-1.48), Pitt score (aOR: 1.72; 95% CI: 1.35-2.17), and lymphocyte count ≤500 cells/μL at presentation (aOR: 3.16; 95% CI: 1.42-7.06) predicted therapeutic failure at day 30. Carbapenem monotherapy (68.6%, primarily meropenem) was the most frequent active therapy, followed by BLBLI monotherapy (10.8%mostly piperacillin-tazobactam). Propensity score (PS)-adjusted models revealed no significant impact of the choice of active therapy (carbapenem-containing vs any other regimen, BLBLI- vs carbapenem-based monotherapy) within the first 72 hours on any of the study outcomes. Conclusions: Our data suggest that active therapy based on BLBLI may be as effective as carbapenem-containing regimens for ESBL-E BSI secondary to UTI in the specific population of KTR. Potential residual confounding and unpowered sample size cannot be excluded (ClinicalTrials.gov identifier: NCT02852902). | |
| local.identifier.orcid | https://orcid.org/0000-0003-0848-3740 | |
| local.publisher.country | Brasil | |
| local.publisher.department | MED - DEPARTAMENTO DE PROPEDÊUTICA COMPLEMENTAR | |
| local.publisher.initials | UFMG | |
| local.url.externa | https://onlinelibrary.wiley.com/doi/10.1111/tid.13520 |
Arquivos
Licença do pacote
1 - 1 de 1